Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
ObservationalEnrolling Location: Multiple care centres across the US
Study to evaluate the effects of the triple-combination modulator, elexacaftor/texacaftor/ivacaftor (PROMISE) , protocol number PROMISE
This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in people with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects people with CF across many different aspects of the disease.
Age:
12 Years and Older
Mutation(s):
Two Copies F508del or One Copy F508del
FEV1% Predicted:
No FEV1 Limit
Number of Visits:
6
Length of Participation:
2 years
Restore CFTR FunctionEnrolling Location: Multiple care centres across the US
Phase 2 study of PTI-808 triple-combination therapy in adults with cystic fibrosis who have at least one copy of the F508del mutation. , protocol number PTI-808-01
This study will look at the safety and tolerability of PTI-808, a modulator intended to help CFTR protein function closer to normal. PTI-808 will be tested in combination with two other modulators, PTI-801 and PTI-428.
18 Years and Older
Two copies F508del or One Copy F508del
40 to 90%
9
10 weeks
Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation. , protocol number AbbVie ABBV-3067
This study will look at the safety and effectiveness of ABBV-3067, a CFTR modulator intended to help CFTR protein function closer to normal. ABBV-3067 will be tested alone and in combination with another CFTR modulator, ABBV-2222. This study has two parts. In Part 1, participants will be randomly assigned to receive one of the following treatments: the study drug ABBV-3067 alone; both ABBV-3067 and ABBV-2222; or a placebo. In Part 2 of the study, some participants will receive both CFTR modulators ABBV-3067 and ABBV-2222, and some participants will receive a placebo. Researchers will test the effectiveness of ABBV-3067 alone and in combination with ABBV-2222 by measuring changes in lung function and sweat chloride. This study may require lung function tests and/or other measurements.
18 years and Older
Two Copies F508del
5
3 months
Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis , protocol number VERTEX VX-18-121-101
This study will look at the safety, tolerability, and effectiveness of the drug VX-121, a drug intended to help CFTR function closer to normal. This study will take place in two parts. Part 1 is randomized and placebo-controlled. This means that some participants will receive the study drug in combination with tezacaftor and VX-561, and some participants will receive placebo. Part 2 is a randomized, active-comparator trial. This means that some participants will receive the study drug in combination with tezacaftor and VX-561, and some participants will receive placebo in combination with tezacaftor and ivacaftor. In this study, researchers will test the safety and tolerability by monitoring for adverse events. They will test for effectiveness by measuring lung function. They will also monitor sweat chloride and how much of the drug stays in the body. This study may require sweat tests, lung function tests, blood samples and/or other measures.
10
17 weeks
Restore CFTR FunctionEnrolling Location: Multiple care centres across the US & Australia
A Phase 2 Study to evaluate efficacy and safety of VX-561 in adults 18 years and older with cystic fibrosis , protocol number NCT03911713 VX-561-101
This study will look at the safety and effectiveness of the drug VX-561, a drug intended to help CFTR function closer to normal. This study is randomized and placebo-controlled. This means that some participants will receive one of four dose levels of the study drug, some participants will receive ivacaftor, and some participants will receive placebo. In this study, researchers will test the effectiveness of VX-561 by monitoring lung function. They will also monitor sweat chloride and adverse events. This study may require lung function tests, blood samples, and/or other measures.
One Copy F508del or No Copies F508del
40 to 100%
8
16 weeks
Anti-InfectiveEnrolling Location: Multiple care centres across the US
Study to evaluate inhaled molgramostim in adults 18 years and older with cystic fibrosis (Savara SAV008-02) , protocol number SAVARA SAV008-02
This study will look at the effectiveness of the inhaled drug molgramostim, a drug intended to treat infections in the lung. This study is open-label with no control. This means that all participants will receive the study drug. In this study, researchers will test the effectiveness of inhaled molgramostim by monitoring NTM cultures. They will also monitor lung function, BMI and quality of life. This study may require sputum samples, lung function tests and/or other measures.
18 years and older
No mutation requirement
30% or greater
19
72 weeks
OtherEnrolling Location: Monash Health - Melbourne
Cystic Fibrosis Related Diabetes (CFRD) Model of care: Optimising Patient Centred Healthcare Delivery in the Inpatient and Outpatient Setting , protocol number RES-18-0000-183 Monash Health Ref RES-18-0000-183 Monash Health Ref
Cystic Fibrosis Related Diabetes Clinical Care Do you have cystic fibrosis related diabetes (CFRD)? Do you feel that clinical services managing CFRD could be improved upon? We want to hear your thoughts on how clinical care for CFRD can be optimised. The purpose of this research is to determine the requirements of adult patients with CFRD. We wish to assess barriers and enablers to provision of optimal care of adults with CFRD with a view to ultimately improving clinical outcomes for all people with CFRD. If you would like to participate, please follow the link to an anonymous survey that should take about 15 minutes to complete. Click here to complete CFRD survey This research has been initiated by the researchers at Monash Medical Centre in Melbourne, Victoria. This project has been approved by Monash Health Human Research Ethics Committee.
Not Specified
Not specified
1
approx. 30 mins
OtherEnrolling Location: NSW - Australia
A Phase 3 multi-centre randomised placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis (COMBATCF). , protocol number NCT01270074 ACTRN12610001072000
The general aim of this project is to conduct a randomized double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The primary outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.
6 Weeks to 6 Months
0
Mucociliary ClearanceEnrolling Location: Australian Sites: Adelaide, Brisbane, Melbourne, Newcastle, Sydney Westmead, Sydney Randwick, Perth
Saline Hypertonic in pre-schoolers + CT (SHIP-CT) , protocol number NCT02950883 & ACTRN12615001067561p SHIP002 (SHIPCT)
The purpose of this study is to assess whether inhalation of 7% hypertonic saline (HS) twice daily for 48 weeks reduces structural lung disease as assessed by computed tomography (CT) in comparison with inhalation of 0.9% isotonic saline (IS) in preschool children (ages 3 to 6) with cystic fibrosis.
3-5 years
A documented genotype with two disease-causing mutations in the CFTR gene
54 weeks
Randomised controlled trial to be determine whether once-daily insulin detemir slows decline in weight and lung functions in patients with cystic fibrosis and early insulin deficiency. , protocol number NCT01100892 ACTRN13611000068965
Cystic fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.
5 Years to 19 Years